Zoetis Inc. (NYSE:ZTS) Stock Holdings Increased by BI Asset Management Fondsmaeglerselskab A S

BI Asset Management Fondsmaeglerselskab A S raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 58.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,931 shares of the company’s stock after acquiring an additional 15,491 shares during the period. BI Asset Management Fondsmaeglerselskab A S’s holdings in Zoetis were worth $7,095,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Peak Financial Advisors LLC bought a new stake in Zoetis during the 4th quarter valued at $2,776,000. Focus Financial Network Inc. ADV bought a new stake in Zoetis during the 4th quarter valued at $2,159,000. Price T Rowe Associates Inc. MD raised its stake in Zoetis by 31.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 13,716,681 shares of the company’s stock valued at $2,707,262,000 after acquiring an additional 3,244,074 shares in the last quarter. Ninety One UK Ltd raised its stake in shares of Zoetis by 13.1% in the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after buying an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Zoetis by 10.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock worth $36,230,000 after buying an additional 17,976 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.2 %

Shares of Zoetis stock traded down $2.17 on Wednesday, reaching $172.07. 365,139 shares of the company were exchanged, compared to its average volume of 2,894,961. The stock has a fifty day moving average price of $171.62 and a 200-day moving average price of $177.52. The firm has a market capitalization of $78.52 billion, a price-to-earnings ratio of 33.57, a price-to-earnings-growth ratio of 2.72 and a beta of 0.86. The company has a current ratio of 3.33, a quick ratio of 1.94 and a debt-to-equity ratio of 1.30. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 2nd. The company reported $1.38 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.04. Zoetis had a return on equity of 50.34% and a net margin of 27.38%. The business had revenue of $2.19 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the previous year, the company posted $1.31 earnings per share. Zoetis’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, analysts expect that Zoetis Inc. will post 5.76 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be issued a dividend of $0.432 per share. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.00%. Zoetis’s dividend payout ratio is 33.33%.

Insider Activity

In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $151.17, for a total value of $139,529.91. Following the transaction, the executive vice president now owns 14,800 shares in the company, valued at $2,237,316. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.16% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on ZTS. HSBC dropped their price objective on Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research note on Wednesday, May 8th. The Goldman Sachs Group dropped their price objective on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research note on Monday, May 6th. Stifel Nicolaus dropped their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a research note on Tuesday, April 30th. Barclays dropped their price objective on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Finally, Piper Sandler reissued an “overweight” rating and issued a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $211.75.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.